GLP-1 Medicines and Sleep Apnea: Can Tirzepatide Improve Snoring and Sleep?
By Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Ahmedabad
“Doctor, I snore loudly and wake up tired. If I lose weight with Mounjaro, will my sleep apnea get better?” It is a reasonable question—and new clinical research provides an encouraging answer for some patients.
Quick answer: In clinical trials, tirzepatide substantially improved obstructive sleep apnea severity in selected adults with excess weight. But the medicine is not a substitute for a sleep study or prescribed CPAP, and US approval for OSA should not be confused with Indian regulatory indications.
What is obstructive sleep apnea?
Obstructive sleep apnea (OSA) happens when the upper airway repeatedly narrows or closes during sleep, interrupting breathing and sometimes lowering oxygen levels. Typical clues include loud habitual snoring, witnessed breathing pauses, waking up gasping, unrefreshing sleep, morning headache and excessive daytime sleepiness. However, some people with OSA do not report obvious symptoms.
OSA can increase cardiovascular and metabolic risk, including difficulties with blood-pressure and glucose management. Snoring alone does not establish a diagnosis; a sleep study is often needed.
How are weight, sleep apnea and insulin resistance connected?
Fat distribution around the neck, upper airway and abdomen can increase the tendency for airway collapse during sleep. Excess weight is an important risk factor for OSA, although it can also occur in people without excess weight. Repeated sleep disruption and low oxygen levels may worsen insulin resistance, blood pressure, concentration and daytime function.
Weight reduction can lessen OSA severity in many people, but it does not guarantee a cure.
Can tirzepatide improve sleep apnea?
Yes, in carefully studied groups. Tirzepatide acts on both the GIP and GLP-1 receptors and can produce clinically meaningful weight loss. In the SURMOUNT-OSA randomized trials, adults with moderate-to-severe OSA and excess body weight were treated for 52 weeks with tirzepatide or placebo, alongside lifestyle measures. Results showed substantial average improvements in breathing interruptions, body weight, oxygen-related measures and patient-reported sleep outcomes.
These trial outcomes are promising, but they are averages from selected populations; they do not predict an individual patient’s response or mean that every GLP-1 medicine has proven the same OSA benefit.
What did the SURMOUNT-OSA clinical trials find?
The main measure was the apnea–hypopnea index (AHI), or the average number of episodes of absent or reduced breathing per hour of sleep.
| Trial at 52 weeks | Tirzepatide: average AHI change | Placebo: average AHI change |
|---|---|---|
| Trial 1 (participants not using PAP at baseline) | −25.3 events/hour | −5.3 events/hour |
| Trial 2 (participants using PAP at baseline) | −29.3 events/hour | −5.5 events/hour |
The study participants had severe OSA on average at baseline. AHI improvements were statistically significant. Results also showed improvement in other sleep-related measures. These findings should not be interpreted as proving that everyone can discontinue positive airway pressure (PAP) treatment.
Read the original SURMOUNT-OSA trial.
Is tirzepatide approved for sleep apnea in India?
The regulatory distinction matters. In December 2024, the United States FDA approved tirzepatide under the brand Zepbound for adults with excess body weight and moderate-to-severe OSA, alongside diet and physical activity.
In India, CDSCO approval records list tirzepatide for type 2 diabetes and weight management in eligible adults; obstructive sleep apnea may be listed among weight-related comorbidities for the weight-management indication. That is not the same as claiming a separate OSA treatment indication has been approved in India. Patients and prescribers should check the current India-specific product label and prescribing rules before treatment.
Sources: US FDA approval statement and CDSCO drug approval database.
Does semaglutide also treat sleep apnea?
Semaglutide can support weight reduction in eligible patients, and weight loss may improve OSA. However, the specific SURMOUNT-OSA results described above tested tirzepatide, not semaglutide. It would be incorrect to assume identical effects or regulatory indications for every GLP-1 or GIP/GLP-1 medicine.
Can you stop CPAP if you start a GLP-1 medicine?
No—not without reassessment by your sleep specialist. Continuous positive airway pressure (CPAP) or another appropriate airway treatment remains important for many people, particularly with moderate-to-severe OSA. Weight loss may change treatment needs, but a repeat sleep evaluation or specialist review is usually required before changing or discontinuing CPAP.
Untreated OSA can persist even after substantial weight loss. Never use improved snoring alone as proof of resolution.
Who should be assessed for sleep apnea?
Discuss OSA evaluation if you have persistent loud snoring, witnessed pauses in breathing, severe daytime sleepiness, waking with choking, difficult-to-control hypertension or relevant cardiovascular or metabolic conditions. An assessment may include a validated screening questionnaire, examination and a home sleep apnea test or attended polysomnography as indicated.
Sleepiness while driving is a serious safety concern. Avoid driving when excessively sleepy and seek timely medical evaluation.
How to improve sleep and metabolic health alongside treatment
- Work toward sustained, individualized weight reduction where appropriate.
- Maintain regular physical activity and adequate protein intake to protect muscle strength.
- Limit alcohol before bedtime and avoid sedatives unless specifically advised.
- Maintain a consistent sleep schedule and discuss positional treatment when suitable.
- Follow your prescribed CPAP or other OSA treatment consistently.
- Monitor blood pressure, diabetes control and medicine side effects with your care team.
For practical food ideas, see what to eat while taking GLP-1 medicines and how to preserve muscle during medical weight loss.
What are the important safety precautions with tirzepatide?
Common adverse effects include nausea, vomiting, diarrhoea, constipation and reflux. Dehydration, gallbladder problems and pancreatitis-related symptoms require attention. Product-specific contraindications and precautions must be reviewed, including relevant history of medullary thyroid carcinoma or MEN2 where applicable, pregnancy, and interactions with other medicines. Patients who use insulin or sulfonylureas may need a separate plan to prevent hypoglycaemia.
Do not start or increase doses without a prescription or buy medicines from unverified sellers. Treatment eligibility depends on approved indications and an individualized assessment.
Frequently asked questions
Can Mounjaro or tirzepatide reduce snoring?
Snoring may improve as OSA severity and weight decrease, but improvement is not guaranteed. Snoring alone cannot measure treatment success.
Is sleep apnea caused only by weight gain?
No. Airway anatomy, age and other factors matter. People without excess weight can have OSA.
Can tirzepatide replace CPAP?
Not automatically. Continue prescribed PAP treatment until a sleep specialist confirms a safe change.
Does improving sleep apnea help blood sugar?
Sleep and glucose regulation are linked, but improved OSA does not replace diabetes monitoring or treatment.
Is tirzepatide approved specifically for OSA in India?
US approval for OSA should not be confused with Indian labelling. Check the current CDSCO-approved Indian indications with your prescribing clinician.
Should I have a sleep study before starting weight-loss treatment?
Not everyone needs one. People with symptoms or risk factors for OSA should discuss testing with their clinician.
Related articles from our clinic
Read our diabetes and sleep apnea guide, tirzepatide and weight loss overview, health benefits of 5%, 10% and 15% weight loss and maintaining results after stopping GLP-1 medicines.
Consult a GLP-1 and Weight Loss Specialist in Ahmedabad
For individualized assessment of weight, type 2 diabetes, thyroid health and associated sleep problems, consult Dr. Moxit Shah, DM Endocrinology at Vishuddha Diabetes, Thyroid, Weight Loss Clinic.
Address: 104–105, Elite Magnum, Bhuyangdev Cross Road, Ghatlodiya, Ahmedabad – 380061, Gujarat, India.
Appointments: +91 99799 92797
References and disclaimer
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024. SURMOUNT-OSA trials.
- US Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea, December 20, 2024. FDA release.
- Central Drugs Standard Control Organization. Indian drug approvals database.
Medical information is provided for education only. Drug indications and labels can vary by country and change over time. Sleep apnea diagnosis and treatment require individualized care. Never stop CPAP or change prescribed medicines without consulting your healthcare team.
